Immunomedics, Inc.
IMMU, a biopharmaceutical company primarily focused on the
development of monoclonal antibody-based products for the targeted treatment
of cancer, autoimmune and other serious diseases, today announced that
repeated cycles of fractionated doses of its proprietary humanized antibody,
clivatuzumab tetraxetan, labeled with yttrium-90 and given in
combination with gemcitabine, demonstrated therapeutic activity in patients
with advanced, inoperable, pancreatic cancer.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in